Market News Stocks News ETF News Crypto News
Why 10x Genomics (TXG) Stock Is Trading Up Today
By Anthony Lee | November 11, 2025, 12:26 PM
TXG
+1.15%
10x Genomics Inc
What Happened?
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 0.6% in the afternoon session after Canaccord Genuity Group raised its price target on the stock. The analyst firm lifted its target to 9.00 from 6.00 and kept a buy rating on the shares.
This move followed the company's recent quarterly earnings report from November 6th, where it posted results that were better than expected. The company reported earnings per share of (/bin/sh.22), beating the consensus estimate of (/bin/sh.27). Revenue for the quarter also came in higher at 49.00 million, ahead of the 42.50 million that analysts had forecast. Amid the positive news, the stock's price reached a new 52-week high, reflecting strong market performance.
After the initial pop the shares cooled down to 7.11, up 0.1% from previous close.
Is now the time to buy 10x Genomics? Access our full analysis report here.
What Is The Market Telling Us
10x Genomics’s shares are extremely volatile and have had 50 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 4 days ago when the stock gained 14.3% on the news that the company reported third-quarter financial results that beat Wall Street's expectations and provided an upbeat revenue forecast for the fourth quarter. For the third quarter, revenue came in at 49 million, exceeding the consensus estimate of 42.4 million. The company's loss per share of /bin/sh.22 was also narrower than the /bin/sh.28 loss analysts had predicted. Looking ahead, 10x Genomics projected fourth-quarter revenue to be in the range of 54 million to 58 million. The midpoint of this guidance surpassed analysts' forecasts, signaling confidence in its performance. Overall, the strong results and positive outlook appeared to drive investor optimism.
10x Genomics is up 20.6% since the beginning of the year, and at 7.11 per share, has set a new 52-week high. Investors who bought ,000 worth of 10x Genomics’s shares 5 years ago would now be looking at an investment worth 25.24.
While Wall Street chases Nvidia at all-time highs, an under-the-radar semiconductor supplier is dominating a critical AI component these giants can’t build without. Click here to access our full research report.
Mentioned In This Article
TXG
+1.15%
10x Genomics Inc
Latest News
Dec-22
Barclays Turns More Bullish on 10x Genomics, Inc. (TXG) Despite Uneven Research Spending
TXG
Insider Monkey
Dec-22
10x Genomics (TXG) Stock Trades Up, Here Is Why
TXG
StockStory
Dec-17
Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data
TXG
Zacks
Dec-16
Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up
TXG
Zacks
Dec-15
Tempus AI Near 5 Target? Valuation, Upside and Risks
TXG
Zacks
Dec-11
Why 10x Genomics (TXG) Stock Is Nosediving
TXG
StockStory
Dec-07
Life Sciences Tools & Services Stocks Q3 Earnings: 10x Genomics (NASDAQ:TXG) Firing on All Cylinders
TXG
StockStory
Dec-02
Teradyne upgraded, Circle Internet initiated: Wall Street's top analyst calls
TXG
The Fly
Nov-18
3 Reasons to Avoid TXG and 1 Stock to Buy Instead
TXG
StockStory
Nov-18
New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
TXG
PR Newswire
Nov-15
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch
TXG
Insider Monkey
Nov-13
5 Insightful Analyst Questions From 10x Genomics's Q3 Earnings Call
TXG
StockStory
Nov-11
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
TXG
PR Newswire
Nov-11
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat
TXG
Insider Monkey
Nov-11
Why 10x Genomics (TXG) Stock Is Trading Up Today
TXG
StockStory